(0.54%) 5 155.34 points
(0.41%) 38 834 points
(0.61%) 16 255 points
(0.58%) $78.56
(3.41%) $2.22
(1.11%) $2 334.20
(3.48%) $27.62
(0.80%) $973.00
(-0.15%) $0.927
(-0.55%) $10.81
(-0.30%) $0.795
(-0.10%) $91.36
Live Chart Being Loaded With Signals
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives...
Stats | |
---|---|
今日成交量 | 16 510.00 |
平均成交量 | 27 534.00 |
市值 | 1.58B |
EPS | INR0 ( 2024-02-11 ) |
下一个收益日期 | ( INR0 ) 2024-05-27 |
Last Dividend | INR1.000 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 45.27 |
ATR14 | INR0.0950 (0.09%) |
音量 相关性
Bal Pharma Limited 相关性
10 最正相关 | |
---|---|
EMIL.NS | 0.925 |
INDIGOPNTS.NS | 0.921 |
MEDICAMEQ.NS | 0.921 |
GOCOLORS.NS | 0.92 |
NAVNETEDUL.NS | 0.919 |
SABEVENTS.NS | 0.916 |
ASAHISONG.NS | 0.915 |
MCLEODRUSS.NS | 0.912 |
SGL.NS | 0.91 |
IGPL.NS | 0.91 |
10 最负相关 | |
---|---|
RAJRILTD.NS | -0.92 |
4THDIM.NS | -0.915 |
LTGILTBEES.NS | -0.898 |
ISMTLTD.NS | -0.889 |
GNA.NS | -0.865 |
KAYNES.NS | -0.865 |
JINDCOT.NS | -0.858 |
KIRLFER.NS | -0.852 |
SYMPHONY.NS | -0.85 |
SHRIRAMEPC.NS | -0.846 |
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bal Pharma Limited 相关性 - 货币/商品
Bal Pharma Limited 财务报表
Annual | 2022 |
营收: | INR3.04B |
毛利润: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
营收: | INR3.04B |
毛利润: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
营收: | INR2.81B |
毛利润: | INR1.11B (39.64 %) |
EPS: | INR3.79 |
FY | 2021 |
营收: | INR2.51B |
毛利润: | INR993.03M (39.64 %) |
EPS: | INR3.34 |
Financial Reports:
No articles found.
Bal Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.750 | 2006-09-07 |
Last Dividend | INR1.000 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | INR13.00 | -- |
Avg. Dividend % Per Year | 0.69% | -- |
Score | 1.51 | -- |
Div. Sustainability Score | 1.444 | |
Div.Growth Potential Score | 2.51 | |
Div. Directional Score | 1.979 | -- |
Year | Amount | Yield |
---|---|---|
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 1.18% |
2019 | INR1.000 | 1.27% |
2020 | INR0 | 0.00% |
2021 | INR1.000 | 1.78% |
2022 | INR1.000 | 0.79% |
2023 | INR1.000 | 1.09% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SSWL.NS | Dividend Junior | 2023-08-14 | Annually | 20 | 0.30% | |
MSUMI.NS | Dividend Junior | 2023-08-09 | Annually | 3 | 0.60% | |
HIKAL.NS | Dividend Junior | 2023-09-18 | Semi-Annually | 23 | 0.37% | |
BLUEDART.NS | Dividend Junior | 2023-07-19 | Annually | 22 | 0.45% | |
REDINGTON.NS | Dividend Knight | 2023-07-06 | Annually | 18 | 3.28% | |
KPITTECH.NS | Dividend Knight | 2023-08-14 | Annually | 6 | 0.47% | |
FACT.NS | Dividend Junior | 2023-09-22 | Insufficient data to determine frequency | 2 | 0.09% | |
AMRUTANJAN.NS | Dividend Knight | 2023-09-14 | Semi-Annually | 15 | 0.38% | |
TASTYBITE.NS | Dividend Junior | 2023-07-14 | Annually | 8 | 0.01% | |
NH.NS | Dividend Junior | 2023-07-06 | Sporadic | 6 | 0.14% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0142 | 1.500 | 9.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0729 | 1.500 | -0.301 | -0.451 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.455 | 1.000 | -0.572 | -0.572 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 3.67 | 7.34 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.440 | 1.000 | 6.00 | 6.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.667 | -0.667 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.444 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.82 | 1.000 | 6.58 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0729 | 2.50 | -0.193 | -0.451 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 7.34 | [0 - 30] |
dividendYielPercentageTTM | 0.980 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.614 | 1.500 | -7.42 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0612 | 1.000 | -0.970 | 0 | [0.1 - 0.5] |
Total Score | 2.51 |
Bal Pharma Limited
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。